Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Non Operating Income: 2015-2025

Historic Non Operating Income for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to $45.7 million.

  • Spyre Therapeutics' Non Operating Income rose 343.09% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.9 million, marking a year-over-year increase of 319.64%. This contributed to the annual value of -$20.7 million for FY2024, which is 78.54% up from last year.
  • Per Spyre Therapeutics' latest filing, its Non Operating Income stood at $45.7 million for Q3 2025, which was up 775.91% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Non Operating Income peaked at $45.7 million during Q3 2025, and registered a low of -$57.8 million during Q2 2023.
  • In the last 3 years, Spyre Therapeutics' Non Operating Income had a median value of $348,000 in 2023 and averaged -$4.3 million.
  • In the last 5 years, Spyre Therapeutics' Non Operating Income skyrocketed by 2,620.00% in 2022 and then crashed by 53,153.21% in 2023.
  • Over the past 5 years, Spyre Therapeutics' Non Operating Income (Quarterly) stood at -$15,000 in 2021, then skyrocketed by 2,620.00% to $378,000 in 2022, then crashed by 4,667.72% to -$17.3 million in 2023, then spiked by 95.26% to -$818,000 in 2024, then spiked by 343.09% to $45.7 million in 2025.
  • Its last three reported values are $45.7 million in Q3 2025, $5.2 million for Q2 2025, and $8.8 million during Q1 2025.